Samsung Electronics Co., Ltd.

Powei Lin

Kwang Ho Cheong

Seung Hyun Lee

Mi Young Cho

Jae Woong Hwang

Young Jun Koh

Jung Wook Lee

Min-Kyung Kim

Saet Byoul Lee

Christina Yi

Kyung Ah Kim

Bo Gyou Kim

Seungja Oh

Jae-woong Hwang

Geun Woong Kim

Han Na Choi

Jimin Lee

There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.

Bispecific anti-Cmet/anti-Her2 antibodies

An anti-EGFR/anti-HER3 antibody or antigen binding fragment thereof, and a method of preventing and/or treating a cancer using the same.

Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof

An anti-HER2 antibody, an anti-c-Met/anti-HER2 bispecific antibody including the same, method for preparing same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same

A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, 'c-Met/EGFR dual inhibitor') and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.

Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor

An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same

Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.

Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor

There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for treating cancer using the same, and an anti-EGFR scFv fragment.

Anti-c-Met/anti-EGFR bispecific antibodies

Provided is an anti-Her3 antibody or antigen-binding fragment thereof, an anti-c-Met/anti-Her3 bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same.

Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same

An anti-EGFR/anti-HER2 bispecific antibody including an anti-EGFR DARPin and an anti-HER2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-HER2 antibody using an anti-EGFR DARPin.

Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins

A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.

Growing community of inventors

Hwaseong-si, South Korea

Powei Lin